San Diego, CA, United States

HemaQuest Pharmaceuticals

www.hemaquest.com
San Diego, CA, United States

Time filter

Source Type

Patent
HemaQuest Pharmaceuticals and Boston University | Date: 2016-10-27

Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.


The Global Hemoglobinopathie market is accounted for $4.6 billion in 2015 and is expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022. Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government’s awareness programs and advanced diagnostics and therapeutics will fuel the market growth. Research & development and growth across developed and developing economies will provide opportunity for the market growth. Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth. Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth. Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements For more information, please visit https://www.wiseguyreports.com/sample-request/674249-haemoglobinopathies-global-market-outlook-2016-2022


News Article | November 29, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Hemoglobinopathie market is accounted for $4.6 billion in 2015 and is expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022. Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government’s awareness programs and advanced diagnostics and therapeutics will fuel the market growth. Research & development and growth across developed and developing economies will provide opportunity for the market growth.  Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth. Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth. Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific       • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


Patent
HemaQuest Pharmaceuticals and Boston University | Date: 2011-03-11

Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.


Patent
Boston University and HemaQuest Pharmaceuticals | Date: 2010-12-08

Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.


Patent
Boston University and HemaQuest Pharmaceuticals | Date: 2013-06-07

Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.


Patent
HemaQuest Pharmaceuticals and Boston University | Date: 2015-06-02

Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.


Patent
HemaQuest Pharmaceuticals | Date: 2010-07-12

Described herein is a method of detecting and/or quantifying analytes, such as short-chain fatty acids. Analysis for the presence and/or quantity of the small molecule can be performed on a biological sample from a subject. In some embodiments, a liquid chromatography/mass spectrometry (LC-MS/MS) instrumentation is combined with a solid-phase extraction (SPE). Methods of derivatization can also be incorporated with LC-MS/MS and SPE instrumentation to detect and quantify target analytes. In addition to derivation, methods of reconstituting derivatized molecules can also be incorporated with LC-MS/MS and SPE instrumentation to detect and quantify target analytes.


News Article | March 12, 2012
Site: www.xconomy.com

HemaQuest Gets $13M Transfusion in Extension of Series B Financing San Diego-based HemaQuest Pharmaceuticals, a biotech developing small molecule drugs for treating sickle cell disease and other blood disorders, has gotten another capital transfusion after once again extending its Series B financing. In a statement today, HemaQuest says it has raised an additional $13 million to support a mid-stage trial of the company’s lead drug candidate for patients with sickle cell disease. That’s almost equal to the $16 million HemaQuest previously raised in three separate steps of its Series B financing. The participating investors are Aberdare Ventures, De Novo Ventures, Forward Ventures, Latterell Venture Partners, and Lilly Ventures. HemaQuest was founded in Seattle in 2007, and moved its headquarters to San Diego in late 2010 after hiring former Favrille CEO John Longenecker. HemaQuest says its most recent extension should enable the company to complete a planned Phase 2b trial of its lead drug candidate by early 2014. The experimental drug, HQK-1001, belongs to a class of compounds known as Short Chain Fatty Acid Derivatives (SCFADs) that have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory.


News Article | March 16, 2012
Site: www.xconomy.com

A spate of funding deals were disclosed over the past week, including a sizable investment in San Diego’s Allylix, an industrial biotechnology startup. —San Diego’s HemaQuest Pharmaceuticals said it raised $13 million in an extension of its Series B funding round to support a mid-stage trial of its experimental drug for patients with sickle cell disease. HemaQuest said its lead drug candidate is intended to stimulate fetal hemoglobin expression and red blood cell production, which would reduce the likelihood that sickle cell-disease patients will suffer dangerous “pain crises” that require hospitalization. —San Diego-based InflammaGen Therapeutics said it’s has begun a mid-stage clinical trial of an experimental treatment that’s intended to prevent multi-organ failure in patients suffering acute shock. InflammaGen, which is an early-stage startup, also has been seeking to establish a strategic partnership with a pharmaceutical company to advance its treatment. —Germany’s BASF Venture Capital accounted for $13.5 million of $18.2 million in funding raised by San Diego-based Allylix, which is using fermentation technology and genetically engineered yeast to produce specialized flavor and fragrance chemicals. Allylix was founded in 2004 to advance its technology for making terpenes, a group of complex hydrocarbon chemicals typically used as flavor and fragrance enhancers. Avrio Ventures, Cultivian Ventures, and Tate & Lyle also participated in the latest round. —Hello Health, the New York-based subsidiary of Canada’s Myca Health, has been gearing up for a major national expansion of its electronic health records technology, which will be largely subsidized by $10 million in venture funding the company raised earlier this year. As part of its plans, Hello Health formed a partnership in December with San Diego’s Qualcomm (NASDAQ: QCOM) to develop a variety of interconnected medical devices. —Luke’s BioBeat column outlined the benefits of expanding the FDA’s “Accelerated Approval” process, which would enable pharmaceutical companies to launch new drugs targeting serious or life-threatening diseases. Florida Republican Rep. Cliff Stearns and New York Democrat Edolphus Towns have introduced the legislation, H. R. 4132, which was discussed at a public hearing held by the House Energy & Commerce Committee’s Subcommittee on Health. —In its first commercial launch, San Diego medical device maker ImThera Medical said its implantable neurostimulation device for treating obstructive sleep apnea was approved for use in most of Europe. Imthera CEO Marcelo Lima said the new therapy would become available “to patients at key European centers of excellence in the second half of 2012.” The device won its “CE” mark, which enables Imthera to market its device in the 27 member states of the European Union as well as Iceland, Norway, Switzerland, and Liechtenstein. —San Diego’s Paul Sonnier, who used LinkedIn to build the Wireless Health Group into a professional social media network with thousands of subscribers, was named to lead digital health strategy at Popper & Co., an M&A advisory and specialty consulting firm based in Sarasota, FL. Sonnier was previously vice president of partner development at the Wireless-Life Sciences Alliance, a nonprofit industry group based in San Diego.

Loading HemaQuest Pharmaceuticals collaborators
Loading HemaQuest Pharmaceuticals collaborators